Investigating how natural killer cell-derived vesicles can kill multiple myeloma cells
Official title: Molecular Characterization of Anti-Tumor Activity Mediated by Extracellular Vesicles Derived from Natural Killer Cells
Funded at St. Louis VA Medical Center · NIH-11098534 · Data updated 2026-11-12
This study is looking at how tiny particles from special immune cells can help fight multiple myeloma, especially in patients who have been affected by harmful substances like Agent Orange, with the hope of finding new ways to treat this cancer while protecting healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Louis VA Medical Center NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project start | February 1, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX006014-03 |
| Project ID | NIH-11098534 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with multiple myeloma, particularly those who are relapsed or refractory to current therapies.
✕Less likely to help
Patients with early-stage multiple myeloma who are responding well to existing treatments may not benefit from this research.
What this research studies
This research focuses on understanding how extracellular vesicles derived from natural killer (NK) cells can target and kill multiple myeloma (MM) cells. The study aims to explore the mechanisms by which these vesicles operate, particularly in patients who have been exposed to harmful substances like Agent Orange. By utilizing a unique NK cell line developed in the lab, the research will assess the effectiveness of these vesicles in destroying cancer cells while sparing normal cells. This approach could lead to new treatment options for patients with relapsed or refractory MM.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with multiple myeloma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using NK cell therapies for cancer treatment, indicating that this approach could be a viable option for multiple myeloma.
Where this research is happening
-
St. Louis VA Medical Center
St. Louis, United States Active
Researchers
- Principal investigator: Kornbluth, Jacki — St. Louis VA Medical Center
- Study coordinator: Kornbluth, Jacki
Related research
Other NIH-funded projects on the same topics.
-
Epigenetic clues in a kidney disease model linked to FSGS
A study exploring how epigenetic changes influence a common kidney disease (FSGS) using a new model to understand why it happens and how it might be prevented.
-
A close look at aging (senescent) cells in ALS brain and spinal cord
Researchers will map aged (senescent) cells in brain and spinal cord tissue from people with ALS to learn how those cells might drive disease progression.
-
Remote kidney injury triggers and lung inflammation in AKI patients
Researchers are studying how acute kidney injury in patients, especially veterans, leads to lung problems and respiratory failure, with focus on the kidney-to-lung communication and potential targets.
-
Molecular clues about how enterotoxigenic E. coli causes diarrhea
This project looks at how a nasty gut bacterium (ETEC) causes diarrhea and how human gut cells respond, with the aim of understanding why infections happen and persist.
-
Comparing newer versus older diabetes medicines for heart and kidney health
This project compares newer diabetes medicines (SGLT2 inhibitors and GLP‑1 drugs) with older options to see which are safer and more helpful for adults with type 2 diabetes.
-
Vitamin D and early-life risk of obesity and insulin resistance
This project tests whether giving vitamin D during pregnancy helps prevent children from becoming obese or insulin-resistant.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.